Research programme: cancer therapeutics - Abiogen/University of Texas

Drug Profile

Research programme: cancer therapeutics - Abiogen/University of Texas

Alternative Names: cUV3; Moab-Anti-CD 54; Platinum-Cholic Acid Complex; PT-C

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abiogen Pharma; University of Texas Southwestern Medical Center
  • Class Cholic acids; Monoclonal antibodies; Platinum complexes
  • Mechanism of Action CD antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma; Multiple myeloma
  • Discontinued Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
  • 30 Jul 2010 Preclinical development of the anti-CD54 monoclonal antibody cUV3 is ongoing in Italy for Malignant ocular melanoma and Multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top